共 50 条
Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review
被引:2
|作者:
Ahmad, Zeeshanuddin
[1
]
Jain, Amar
[1
]
Mehta, Nikhil
[1
]
Saldanha, Elroy
[1
]
Patel, Dhruv
[1
]
Desai, Sanjay M.
[1
]
机构:
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词:
Epithelial ovarian cancer (EOC);
Primary cytoreductive surgery (PCS);
Interval debulking surgery (IDS);
Neoadjuvant chemotherapy (NACT);
ADVANCED-STAGE OVARIAN;
EXPLORATORY ANALYSIS;
SURVIVAL;
CARCINOMA;
TIME;
D O I:
10.1007/s40944-018-0253-2
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
收藏
页数:4
相关论文